Neurocrine CEO Kevin Gorman to retire Oct 11; Kyle Gano appointed successor

NEUROCRINE BIOSCIENCES INC

Kevin C. Gorman, Ph.D. to retire as President and CEO effective October 11, 2024; will remain on the board.
Kyle Gano, Ph.D., current Chief Business Development and Strategy Officer, becomes President and CEO on same date.
Gano appointed to the board as a Class II director effective October 11, 2024.
Board size increased from 10 to 11 via bylaw amendment to accommodate Gano's appointment.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kevin C. Gorman

President and Chief Executive Officer

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2024-10-11
Successor: Kyle Gano
Filed: May 28, 2024, 7:59 PM ET

Kevin C. Gorman, Ph.D. will retire as Neurocrine’s President and Chief Executive Officer effective as of October 11, 2024 (the “Transition Date”).

Appointed

Kyle Gano

Class II Director

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2024-10-11
Filed: May 28, 2024, 7:59 PM ET

effective as of the Transition Date, Dr. Gano has been appointed to the Board as a Class II director to serve until Neurocrine’s 2025 annual meeting of stockholders.

Appointed

Kyle Gano

President and Chief Executive Officer

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2024-10-11
Filed: May 28, 2024, 7:59 PM ET

appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kevin C. Gorman retired as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.

Action: retired
Role: President and Chief Executive Officer

Exact text from the filing

Kevin C. Gorman, Ph.D. will retire as Neurocrine’s President and Chief Executive Officer effective as of October 11, 2024 (the “Transition Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kyle Gano was appointed as Class II Director at NEUROCRINE BIOSCIENCES INC.

Action: appointed
Role: Class II Director

Exact text from the filing

effective as of the Transition Date, Dr. Gano has been appointed to the Board as a Class II director to serve until Neurocrine’s 2025 annual meeting of stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kyle Gano was appointed as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.

View on SEC.gov

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001193125-24-148107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.